American Society of Hematology

banner image

CME, MOC, and Certificates of Attendance

Obtain CME/MOC or request a Certificate of Attendance for the 61st ASH Annual Meeting.

Learn more
banner image

2020 Highlights of ASH

Discuss the latest developments with leading hematology faculty in nine exciting locations worldwide.

Register today
banner image

Medical Student and Early-Career Investigator Awards

ASH has several sponsored hands-on research opportunities.

Learn more
Find a Hematologist

Find a Hematologist

Search a database of practicing hematologists in your area.

Learn more
Support Hematology

ASH Foundation

Help move hematology forward by supporting research, career development, and quality care and education programs.

Learn more
Join ASH

ASH Membership

Become part of a global network of more than 17,000 hematologists working to conquer blood diseases.

Learn more
  • Encouraging Results Seen with Novel Approach to Gene Therapy for Sickle Cell Disease

    Three adult patients with sickle cell disease (SCD) are doing well after receiving an infusion of their own stem cells that had been genetically engineered to induce them to stop producing harmful “sickle” hemoglobin and start producing a healthy form of hemoglobin, according to a study presented today during the 61st American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando.

  • Immunotherapy Superior to Chemotherapy for Children with Relapsed B-ALL

    The immunotherapy drug blinatumomab significantly improved survival in children with relapsed B-acute lymphoblastic leukemia (B-ALL) compared with standard chemotherapy in a study presented today during the 61st American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando.

  • New Drug Markedly Improves Overall Survival in Patients with AML in Remission

    Using an investigational oral form of azacitidine therapy, CC-486, significantly improved overall survival in older patients with newly diagnosed acute myeloid leukemia (AML) who were in remission following standard induction chemotherapy with or without consolidation therapy, according to a phase III study presented today during the 61st American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando.

  • Phase III Trial Finds Sutimlimab Effective Against Cold Agglutinin Disease

    Patients with cold agglutinin disease (CAD) had improved hemoglobin levels, required fewer blood transfusions, and felt significantly less fatigued after receiving the experimental drug sutimlimab for 26 weeks in a phase III clinical trial.

View all press releases
  • CAR T-cell Therapy: An Update on Coverage and Reimbursement

    ASH continues to advocate for adequate coverage and reimbursement for chimeric antigen receptor T-cell (CAR-T) therapy. In early August, the Centers for Medicare and Medicaid Services (CMS) finalized policies impacting both reimbursement of and coverage for CAR-T therapy. The final Inpatient Prospective Payment System (IPPS) rule, published on August 2, and the final Decision Memo for CAR T-cell Therapy for Cancers, issued August 7.

  • 2018 ASH Advocacy Activities

    ASH continues to increase its efforts to expand and enhance the Society’s reach. NIH funding, efforts to ensure patient access to drugs, and sickle cell disease were top priorities on ASH’s advocacy agenda in 2018.

  • 2018 ASH Advocacy Efforts Related to Sickle Cell Disease and Sickle Cell Trait

    ASH continues to invest in and explore the important actions needed to make a significant difference in sickle cell disease (SCD) access to care, research, and global issues. Learn about the major advocacy-related initiatives undertaken by ASH in 2018.

  • 2018 ASH Advocacy Efforts to Ensure Patient Access to Care

    In 2018, ASH worked to ensure patient access to care through a number of methods including ensuring drug access, pain management-related issues, and the Affordable Care Act.

View all policy news
View all Hematologist articles